Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplemental Figure 1 A B C.

Published byMarcelo Alcântara Covalski Modified over 6 years ago

Similar presentations

Presentation on theme: "Supplemental Figure 1 A B C."— Presentation transcript:

1 Supplemental Figure 1 A B C

2 Supplemental Figure 2 57 kDa 70 kDa c-myc β-actin 42 kDa RWPE-1 DU-145
PC-3 PC-3-ML AR-CaP-E AR-CaP-M c-myc β-actin 42 kDa

3 Supplemental Figure 3 A B

4 Supplemental Figure 4 pPEG-Luc pAEG-Luc 24h 48h 24h 48h D V L R
PC3-ML PCa-1 PCa-2 PCa-3 PC3-ML PCa-1 PCa-2 PCa-3 PCa-4 Control Ctrl-1 Ctrl-2 Ctrl-3 Control Ctrl-1 Ctrl-2 Ctrl-3

5 Supplemental Figure 5 (Normalized ng Luc pDNA)/(100ng gDNA)
AEG-Prom treated PCa Lungs Tumor PEG-Prom treated NS

6 Supplemental Figure 6 T A B C D E Gross H&E IHC(Anti-Luc) Pathology
In-vivo BLI Ex-vivo BLI Gross H&E IHC(Anti-Luc) Pathology A B C D T E

7 Supplemental Figure 7 A B PC3-ML Control PCa-1 Ctrl-1 PCa-2 Ctrl-2

8 Supplemental Figure 8 L2 B A L2 L1 L3, L4 L5 C

Download ppt "Supplemental Figure 1 A B C."

Similar presentations

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.
Supplementary Figure 1. Caspase 8 expression and activation and Fas expression in NSCLC and normal lung cell lines. A Western blot analysis of DR4 and.

Supplementary Figure 1. Caspase 8 expression and activation and Fas expression in NSCLC and normal lung cell lines. A Western blot analysis of DR4 and.
Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
Figure 1 HuR Tis11b HPRT VEGF 0 1 2 3 4 5Time (h) A 462 bp (VEGF 165 ) 332 bp (VEGF 121 ) 354 bp 111 bp 305 bp.

Figure 1 HuR Tis11b HPRT VEGF Time (h) A 462 bp (VEGF 165 ) 332 bp (VEGF 121 ) 354 bp 111 bp 305 bp.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Supplement Figure 1A. Representative 2D gel image of normal whey with 32 differently expressed protein spots identified by peptide mass fingerprinting.

Supplement Figure 1A. Representative 2D gel image of normal whey with 32 differently expressed protein spots identified by peptide mass fingerprinting.
Supplemental Results Online Figure S1. Norepinephrine increases ROS production. (A): H9c2 cells were treated with 10  M norepinephrine and intracellular.

Supplemental Results Online Figure S1. Norepinephrine increases ROS production. (A): H9c2 cells were treated with 10  M norepinephrine and intracellular.
0 1000 2000 3000 4000 5000 020406080100120 ADT, Estramustine, Dexamethasone Prednisolone Radiotherapy (Months) (ng/mL) PSA Time Patient A Patient B Patient.

ADT, Estramustine, Dexamethasone Prednisolone Radiotherapy (Months) (ng/mL) PSA Time Patient A Patient B Patient.
Scientific Notation. Write the following numbers in scientific notation: Ex:3,700,000 km ___________________________ Ex:0.00000000094 g ________________________.

Scientific Notation. Write the following numbers in scientific notation: Ex:3,700,000 km ___________________________ Ex: g ________________________.
Supplemental Table 1 Source and authentication of cell lines.

Supplemental Table 1 Source and authentication of cell lines.
Ex Vivo Gene Therapy Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model Tagan A. Griffin, Hayley C. Anderson,

Ex Vivo Gene Therapy Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model Tagan A. Griffin, Hayley C. Anderson,
Supplemental Figure 1. Erlotinib does not alter oxygenation of tumors. Tumor pO 2 was measured by phosphorescence lifetime oximetry at times before erlotinib.

Supplemental Figure 1. Erlotinib does not alter oxygenation of tumors. Tumor pO 2 was measured by phosphorescence lifetime oximetry at times before erlotinib.
Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.

Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.
Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
1. 3.27 M 2. 79.5 M 3. 0.135 M 4. 7.43 M 5. Not Listed 1234567891011121314151617181920 21222324252627282930.

M M M M 5. Not Listed
A B Supplementary Figure S1. T790M CTC PointMan genotyping assay. (A) Test characteristics of PointMan CTC T790M genotyping assay. The assay was validated.

A B Supplementary Figure S1. T790M CTC PointMan genotyping assay. (A) Test characteristics of PointMan CTC T790M genotyping assay. The assay was validated.
Supplemental Table 1. Phenotypes in sleepy1 mutants. Fertility (number of seeds/one silique) Stem (cm) (after 60 days) Leaf (color) sly1-t2 (WS)dark green19.7.

Supplemental Table 1. Phenotypes in sleepy1 mutants. Fertility (number of seeds/one silique) Stem (cm) (after 60 days) Leaf (color) sly1-t2 (WS)dark green19.7.

營 建 工 地 的 噪 音 第十組 組員 : 蘇 敏 益 4970N014 徐 鴻 廣 4970N024 林 孟 賢 4970N012 葉 書 甫 4970N013.

營 建 工 地 的 噪 音 第十組 組員 : 蘇 敏 益 4970N014 徐 鴻 廣 4970N024 林 孟 賢 4970N012 葉 書 甫 4970N013.

Similar presentations

Ads by Google